Document is current
Any future updates will be listed below
-
Authors
Alharbi, Arwaf S. https://orcid.org/0000-0003-3694-1067
Sapkota, Sunil https://orcid.org/0000-0001-7901-9879
Zhang, Zhikuan
Jin, Ruitao
Rupasinghe, Erandi
Jayasekara, W. Samantha N.
Yu, Dingyi
Speir, Mary
Wilkinson-White, Lorna
Cubeddu, Liza
Ellyard, Julia I. https://orcid.org/0000-0001-6301-2533
Rezwan, Refaya https://orcid.org/0000-0002-2859-2461
Wenholz, Daniel S.
McAllan, Alexandra L. https://orcid.org/0000-0002-8545-8285
Gao, Rui
Ying, Le
Sathiqu, Rasan M.
Hosseini Far, Hani
Bones, Josiah
He, Sitong
Alexander, Marina R.
Lennox, Kim A.
Hertzog, Paul J. https://orcid.org/0000-0002-1373-8472
Nold-Petry, Claudia A. https://orcid.org/0000-0002-7439-3834
Stewart, Cameron R.
Vinuesa, Carola G. https://orcid.org/0000-0001-9799-0298
Behlke, Mark A.
Ohto, Umeharu
Laczka, Olivier F. https://orcid.org/0000-0003-0966-9897
Gamsjaeger, Roland
Corry, Ben https://orcid.org/0000-0002-6324-442X
Shimizu, Toshiyuki https://orcid.org/0000-0002-0547-8922
Gantier, Michael P. https://orcid.org/0000-0003-3740-698X
- License Information
-
More Information
Article History
Received: 6 June 2025
Accepted: 8 January 2026
First Online: 10 February 2026
Competing interests
: O.F.L., D.S.W. and M.S. are employees of Noxopharm and Pharmorage. M.P.G. and B.C.’s groups receive funding from Noxopharm to study the activity of oligonucleotides on TLR7/8. M.P.G. receives consulting and advisory fees from Noxopharm. M.P.G. does not personally own shares and/or equity in Noxopharm. M.P.G., O.F.L., D.S.W., M.S. and S.S. are named inventors of a patent relating to the trimer oligonucleotide technology developed herein (WO2024077351). O.F.L. owns shares and/or equity in Noxopharm. The other authors declare no competing interests.
